News | February 23, 2009

Alsius Corp. Agrees to Sell Temperature Management Assets to ZOLL

February 23, 2009 - Alsius Corp. said today it has signed an agreement with a subsidiary of ZOLL Medical Corp. under which Alsius will sell to ZOLL substantially all the assets constituting Alsius’ intravascular temperature management device business for a purchase price of $12 million in cash.

The assets to be acquired include the intellectual property relating to the business, other intangibles, inventories and fixed assets. The closing of the transaction is subject to customary closing conditions. Alsius makes intravascular temperature management devices to induced hypothermia used in heart attack and trauma patients. The device can also be used to warm patients during surgical procedures.

“As we considered various options for Alsius in today's tough financing and capital spending environment, we determined that the sale to ZOLL is in the best interests of our stockholders, and a positive result for our customers and the patients who need our products,” said William Worthen, Alsius’ president and CEO. “ZOLL’s significant investment in and knowledge of critical care hospital products and considerable financial strength will serve to ensure that Alsius’ solutions for temperature management continue to be provided and supported.”

Alsius intends to prepare an information statement that will be filed with the SEC and disseminated to all Alsius stockholders to report in detail on the terms and provisions of the transaction and the winding down of its affairs following the consummation of the transaction, including how it will use the $12 million in proceeds to repay indebtedness, transaction expenses and other costs. Following the settlement of all liabilities, Alsius will distribute its remaining cash, if any, to its stockholders. Alsius’ preliminary estimate is that there will be approximately $7.6 million, or 34 cents per share of common stock, available for distribution over time to its stockholders with the final distribution amount to be determined and the final distribution made after settlement and satisfaction of liabilities. However, if liabilities are greater than estimated, or if unknown liabilities are incurred, then the amount available for distribution will be less than 34 cents (or could be greater if liabilities are less than expected).

For more information: www.alsius.com

Related Content

therapeutic hypothermia, children, cardiac arrest, treatment, temperature
Feature | May 04, 2015
A large-scale, multicenter study has shown that therapeutic hypothermia does not improve survival rates or reduce brain...
News | December 11, 2014
Researchers at Okayama University in collaboration with several medical centers in Japan have demonstrated the safety...
Feature | September 19, 2014
September 19, 2014 — According to a new study, peritoneal hypothermia is feasible for patients who have suffered ST-...
Technology | July 10, 2014
July 10, 2014 — Life Recovery Systems announced the U.S. Food and Drug Administration (FDA) has approved two...
therapeutic hypothermia, Philips InnerCool

The Philips InnerCool RTx system was used in the CHILL-MI study for use in STEMI patients.

Feature | February 03, 2014 | Dave Fornell
Use of therapeutic hypothermia is used to prevent neurological damage in patients who suffer sudden cardiac arrest (SCA...
BeneChill RhinoChill Therapeutic Hypothermia Cath Lab Intranasal Cooling System
News | January 22, 2014
BeneChill Inc. received the 2014 Frost & Sullivan Award for Technology Innovation Leadership for its RhinoChill...
rhinochill, RhinoChill, benechill, BeneChill

RhinoChill IntraNasal Cooling System

News | December 03, 2013
With the benefits of conventional strategies for therapeutic hypothermia following cardiac arrest being called in to ...
therapeutic hypothermia temperature management cath lab clinical trial study
Feature | November 01, 2013
clinical trial shows that rapidly cooling...
News | October 01, 2013
The Cardiovascular Research Foundation (CRF) announced the late breaking trials and first report investigations that...
News | August 06, 2013
Vanderbilt Heart and Vascular Institute is participating in the VELOCITY study, a randomized controlled clinical study...
Overlay Init